Kurma Partners (Kurma) has teamed up with Insitut Pasteur to launch its third fund Kurma Diagnostics (KDx), a venture capital fund Venture Capital fund dedicated to financing early-stage European innovative Diagnostic projects and companies.
The new fund supported by the European Investment Fund, Fonds National d’Amorçage, Institut Pasteur, and BNP Paribas, will benefit from the extensive network of European clinical and academic research institutes that has been cultivated over the past six years.
To date, Kurma has made investments across Europe via two funds, in therapeutics, devices, and diagnostics companies, and has demonstrated its value as a financial and commercially oriented partner to manage the growth of a diverse range of life science investments. Investments have covered the full development spectrum from early (company creation) projects right the way through to growth capital opportunities.
KDx has a dedicated team that is completely focused on the sector. The fund will look at the full scope of diagnostic opportunities; from imaging systems, software, sample collection and management, biomarkers all the way through to platform technologies and e-health systems.
The diagnostic space is rapidly growing and evolving, creating both challenges and opportunities.
A key feature of the fund will be its ability to seed fund projects at pre-industrialisation stage within a 12-24 month period, and incorporate them into a specifically designed accelerator during this early phase.
